The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease

被引:43
作者
Kastelein, JJP
Groenemeyer, BD
Hallman, DM
Henderson, H
Reymer, PWA
Gagne, SE
Jansen, H
Seidell, JC
Kromhout, D
Jukema, JW
Bruschke, AVG
Boerwinkle, E
Hayden, MR
机构
[1] Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z4, Canada
[2] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Texas, Sch Publ Hlth, Houston Hlth Sci Ctr, Ctr Human Genet, Houston, TX USA
[4] Natl Inst Publ Hlth & Environm Protect, Dept Chron Dis & Environm Epidemiol, NL-3720 BA Bilthoven, Netherlands
[5] Leiden Univ, Dept Cardiol, Leiden, Netherlands
[6] Univ Cape Town, Dept Chem Pathol, ZA-7925 Cape Town, South Africa
[7] Erasmus Univ, Dept Biochem, NL-3000 DR Rotterdam, Netherlands
关键词
coronary artery disease; dyslipidaemia; lipoprotein lipase; mutation;
D O I
10.1034/j.1399-0004.1998.531530106.x
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Two mutations in the lipoprotein lipase (LPL) gene, a T to G transition at position -93 of the proximal promoter region and an Asp9Asn substitution in exon 2, were examined in 762 Dutch males with angiographically-diagnosed coronary artery disease (CAD) and 296 healthy normolipidemic Dutch males. The two mutations exhibited strong linkage disequilibrium (D' = 0.975). A significantly higher proportion of cases (4.86%) than controls (1.37%) carried the -93G/Asn9 allele (p = 0.008). In the combined sample of cases and controls, adjusted mean plasma total cholesterol (TC) levels were significantly higher in -93G/Asn9 carriers (6.20 +/- 0.13 mmol/l) than in non-carriers (5.93 +/- 0.03 mmol/l; p = 0.048), while mean high-density lipoprotein cholesterol (HDL-C) levels were lower in carriers (0.88 +/- 0.03 mmol/l) than in non-carriers (0.98 +/- 0.01 mmol/l; p = 0.002). There was a trend towards higher triglyceride (TG) levels in carriers (1.96 +/- 0.14 mmol/l) compared with non-carriers (1.73 +/- 0.03 mmol/l) (p = 0.08). Addition ally, carrier frequencies in tertiles of TC, HDL-C, TG, and LPL activity, suggested an association of the -93G/Asn9 variant with higher TC and TG levels, and with lower HDL-C and LPL activity levels. Logistic regression revealed a significant odds ratio (OR) for the combined -93G/Asn9 genotype in CAD cases relative to controls (OR: 5.36; 95% CI: 1.57-18.24), with age, body mass index (BMI), smoking, and plasma total-and HDL-cholesterol levels included in the model. In conclusion, we show that the LPL Asp9Asn mutation is in non-random association with a T -->G substitution at position -93 of the proximal promoter region and that the combined -93G/Asn9 genotype predisposes to decreased HDL-C levels and an increased risk of CAD.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 32 条
[1]   The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial [J].
Alaupovic, P ;
Mack, WJ ;
KnightGibson, C ;
Hodis, HN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (04) :715-722
[2]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[3]   ROLE OF TRIGLYCERIDES IN CORONARY-ARTERY DISEASE - LESSONS FROM THE PROSPECTIVE CARDIOVASCULAR MUNSTER STUDY [J].
ASSMANN, G ;
SCHULTE, H .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (19) :H10-H13
[4]   DETECTION AND CHARACTERIZATION OF THE HETEROZYGOTE STATE FOR LIPOPROTEIN-LIPASE DEFICIENCY [J].
BABIRAK, SP ;
IVERIUS, PH ;
FUJIMOTO, WY ;
BRUNZELL, JD .
ARTERIOSCLEROSIS, 1989, 9 (03) :326-334
[5]  
Bijvoet S, 1996, J LIPID RES, V37, P640
[6]   Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250->Asn; Ser251->Cys) resulting in lipoprotein lipase (LPL) deficiency [J].
Bijvoet, SM ;
Wiebusch, H ;
Ma, Y ;
Reymer, PWA ;
Bruin, T ;
Bakker, HD ;
Funke, H ;
Assmann, G ;
Hayden, MR ;
Kastelein, JJP .
NETHERLANDS JOURNAL OF MEDICINE, 1996, 49 (05) :189-195
[7]   PREDICTION OF ANGIOGRAPHIC CHANGE IN NATIVE HUMAN CORONARY-ARTERIES AND AORTOCORONARY BYPASS GRAFTS - LIPID AND NONLIPID FACTORS [J].
BLANKENHORN, DH ;
ALAUPOVIC, P ;
WICKHAM, E ;
CHIN, HP ;
AZEN, SP .
CIRCULATION, 1990, 81 (02) :470-476
[8]  
Brunzell JD, 1995, METABOLIC MOL BASES, P1913
[9]  
BUCOLO G, 1973, CLIN CHEM, V19, P476
[10]   EPIDEMIOLOGY OF TRIGLYCERIDES - A VIEW FROM FRAMINGHAM [J].
CASTELLI, WP .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (19) :H3-H9